Therefore, we hypothesized that analyzing diverse gait parameters, that can capture distinct properties of gait, in conjunction with a range of plasma biomarkers, may shed light on how early neurodegeneration (measured by NfL and GFAP) and AD neuropathology (measured by Aβ 42/40 ratio and P-Tau181) impacts motor performance. The gene discussed is GFAP; the disease is Alzheimer disease.